Clinical Trials Logo

Clinical Trial Summary

The Investigator postulate that the use of PESI in addition to routine clinical practice, as opposed to routine clinical practice based on clinical judgment alone, will help physicians to correctly identify PE patients at low-risk of adverse outcomes. Considered that low-risk patients could benefit from a short hospital stay, aim of this study is to demonstrate that the use of PESI will lead physicians to discharge these patients earlier, thus reducing the duration of hospital stay of PE patients (primary outcome). Outpatients diagnosed with PE at the emergency department (ED) and admitted to participating units represent the target population As the availability of DOACs may influence the duration of hospital stay, the secondary objectives of the present study are: 1. to demonstrate that a shorter hospital stay for low-risk PE patients (independently on the method used to identify them) will reduce the incidence of hospital-associated complications and improve patients satisfaction and quality of life, without increasing the incidence of PE-related complications 2. to demonstrate that the use of PESI, as opposed to clinical judgment alone, will be associated with a greater proportion of patients discharged early (< 72 hours from ED admission) or treated entirely at home (< 24 hours from ED admission). 3. to demonstrate that the use of DOACs will reduce the duration of hospital stay of PE patients 4. to demonstrate that the use of DOACs, as opposed to standard treatment, will be associated with a greater proportion of patients discharged early (< 72 hours from ED admission) or treated entirely at home (< 24 hours from ED admission).


Clinical Trial Description

STUDY DESIGN Within 24 hours from acute PE diagnosis, each treating physician (local Investigator) will be centrally randomized. Treating physicians (local Investigator) of the participating Units will call the coordinating centres by phone for randomization. Before randomization, in order to avoid any influence on treatment choice, each treating physician (local Investigator) should declare in advance which treatment strategy will use for his patient (intention-to-treat), i.e. standard treatment with heparin plus vitamin K antagonist (standard group) or DOACs (DOACs group) Randomization will be stratified by treatment choice of the local Investigator. Each of two 'intention-to-treat' approaches will be therefore randomized to two arms, i.e. arm 1 or arm 2. Arm 1: treating physicians must formally calculate PESI and report in the clinical record form* each day of hospitalization on top of routine clinical practice (standard care) Arm 2: standard care (i.e. no formally calculation of PESI on top) Randomization will be performed centrally with a 1:1 ratio, following a computer-generated list of randomization. STUDY POPULATION 1.1 Population Randomised physicians: Each Local Investigator of participating canters. All participating centres are Internal Medicine Unit. PE population: Consecutive adult outpatients of any age, gender and race, with an objectively confirmed diagnosis of a suspected or unsuspected acute PE at the emergency department (ED) and admitted to participating units will be included. Suspected PE means that diagnosis has been made by an imaging test (computed tomographic pulmonary angiography [CTPA], pulmonary angiography, V/Q lung scan) prescribed by a treating physician who had clinical suspicion of PE. Unsuspected PE means that diagnosis has been made incidentally by an imaging test performed for other clinical indications (e.g. cancer staging or follow-up). Objective diagnosis of acute PE means: a positive computed tomographic pulmonary angiography (CTPA), a positive pulmonary angiography, a high-probability V/Q lung scan (or perfusion lung scan with negative chest X-ray), or intermediate probability V/Q or perfusion lung scan with proximal deep-vein thrombosis (DVT) documented by compression ultrasonography. 1.2 Sample size calculation The Investigators hypothesize that the distribution of hospital stay duration for PE will have a standard deviation of 4 days. The I vestigators also hypothesize that the mean duration of hospital stay will be reduced by at least 15% in PE patients whose treating physician will be randomised to formally use PESI and by 5% in PE patients whose treating physician will not be randomised to formally calculate PESI. Low-risk PE patients are almost 50% of all PE population. Therefore, with an α error of 0.05 and a statistical power (1-β error) of 80%, 200 patients for each group (a total of 400 patients) need to be enrolled to find a statistically significant difference (p<0.05) between the mean hospital stay length. As the variable 'hospital stay length' will have a non-normal distribution and needs to be expressed and reported as median, 10% extra patients need to be enrolled to reach a statistically significant difference with the previous statistical assumptions. Final total sample size will be, therefore, of 440 patients (220 patients for each group) OUTCOMES 1. Main study parameter/endpoint The primary outcome is the median length of hospital stay 2. Secondary study parameters/endpoints The secondary efficacy outcomes will be the following: 1. health-system measures - proportion of patients undergoing short-hospital stay - proportion of patients undergoing complete home-treatment - post-discharge hospital re-admission - post-discharge outpatient visits to emergency department 2. patient-related outcomes - quality of life (5-point Likert scale questionnaire) The safety outcomes will be the following: 1. overall mortality 2. PE-related - PE-related mortality - recurrent PE and/or deep vein thrombosis (DVT) - major bleeding - clinically relevant non-major bleeding - minor bleeding - other anticoagulation-related complications (hematoma/infection at heparin or fondaparinux injection sites, heparin-induced thrombocytopenia) 3. Hospitalization-related - hospital-acquired infections (pneumonia; urinary tract infection; other) - iatrogenic complications - immobilization syndrome - pressure sores Overall mortality, PE-related safety outcomes, post-discharge hospital re-admission and outpatient visits to emergency department will be measured at 14 days, 30 days, and 90 days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03002467
Study type Interventional
Source Università degli Studi dell'Insubria
Contact
Status Terminated
Phase N/A
Start date September 2016
Completion date December 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Completed NCT03915925 - Short-term Clinical Deterioration After Acute Pulmonary Embolism
Active, not recruiting NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Completed NCT04454554 - Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
Recruiting NCT03173066 - Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography Phase 1
Not yet recruiting NCT04430569 - Pulmonary Embolism International THrOmbolysis Study-3 Phase 3
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02611115 - Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography. N/A
Completed NCT01975090 - The SENTRY Clinical Study N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT01326507 - Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT02476526 - Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Phase 4
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00780767 - Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism Phase 2
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2
Completed NCT00816920 - Natural History of Isolated Deep Vein Thrombosis of the Calf
Completed NCT00233740 - Protection From Pulmonary Embolism With the Permanent OptEase™ Filter (PROOF) Phase 4
Completed NCT00264277 - D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism Phase 4